Clinical Trials

42 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT06959537 2026-05-20

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

24 enrolled

Breast Neoplasms

NCT04318678 2026-05-19

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

LymphoidMyeloidOther hematologic neoplasm

108 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04897321 2026-05-19

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

CNSDermatologicGastrointestinalGenitourinarySarcoma

48 enrolled

Adrenal Cortex Neoplasms, Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05989828 2026-05-19

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT06305299 2026-05-19

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

27 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT06777979 2026-05-19

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

30 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07257419 2026-05-19

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

LymphoidOther hematologic neoplasm

70 enrolled

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06066424 2026-05-15

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

54 enrolled

Other solid neoplasm

Solid Tumors

NCT07194044 2026-05-15

METTSEO

15 enrolled

Sarcoma

Sarcoma, Ewing

NCT06879340 2026-05-14

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

54 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT06698744 2026-05-13

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Withdrawn

Plasma cell

Multiple Myeloma

NCT07583303 2026-05-13

BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

19 enrolled

Leukemia, Myeloid, Acute

NCT05020444 2026-05-12

TriPRIL CAR T Cells in Multiple Myeloma

18 enrolled

Plasma cell

Multiple Myeloma

NCT05088356 2026-05-12

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

MyeloidOther hematologic neoplasm

66 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

MyeloidOther hematologic neoplasm

15 enrolled

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07444632 2026-05-08

Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies

60 enrolled

Hodgkin Disease

NCT05849207 2026-05-07

GeriBMT

Hematologic Neoplasms

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT07101432 2026-05-06

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

33 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05400109 2026-05-05

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

21 enrolled

Lymphoma, Non-Hodgkin

NCT00641381 2026-05-04

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

DermatologicLymphoidOther hematologic neoplasm

25 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05621668 2026-05-04

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

40 enrolled

Sarcoma

Bone Neoplasms, Sarcoma

NCT07564232 2026-05-04

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

40 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05707273 2026-04-24

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

18 enrolled

Burkitt Lymphoma

NCT00872625 2026-04-23

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Breast Neoplasms

NCT07548983 2026-04-23

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

40 enrolled

Leukemia, Myeloid, Acute

NCT01953900 2026-04-22

VEGAS

CNSSarcoma

Chickenpox, Neuroblastoma, Osteosarcoma

NCT06347068 2026-04-22

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

42 enrolled

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT03655002 2026-04-20

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

8 enrolled

Carcinoma, Hepatocellular

NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

21 enrolled

Dermatologic

Melanoma, Neoplasms

NCT06083883 2026-04-16

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

44 enrolled

Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

NCT06464965 2026-04-16

Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer

10 enrolled

Stomach Neoplasms

NCT06660420 2026-04-16

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

39 enrolled

Dermatologic

Melanoma

NCT01955460 2026-04-15

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

34 enrolled

Dermatologic

Melanoma

NCT02379520 2026-04-15

HESTIA

32 enrolled

Neoplasms, Recurrence

NCT03710421 2026-04-15

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

30 enrolled

Plasma cell

Multiple Myeloma

NCT04177004 2026-04-15

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Phase 1 Suspended

53 enrolled

Hematologic Neoplasms

NCT06968195 2026-04-15

Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

Phase 1 Suspended

24 enrolled

Carcinoma, Hepatocellular

NCT07166419 2026-04-15

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

LymphoidMyeloidOther hematologic neoplasm

24 enrolled

Blast Crisis, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT04895761 2026-04-13

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

6 enrolled

Breast Neoplasms

NCT07133997 2026-04-07

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Burkitt Lymphoma

NCT01822652 2026-04-06

GRAIN